SureTrader Stock Hero Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

BTX RSS Feed
Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 5/4/2015 9:16:02 PM - Followers: 63 - Board type: Free - Posts Today: 0

 

BioTime, Inc.  (BTX)

 

 
 

 

http://www.biotimeinc.com/

 

 

 

Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389

 

CIK

0000876343

 

 

BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us

 

The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:
 

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
     
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:  http://www.biotimeinc.com/aboutBT.htm

 

 

 

 

 

 

Management: 

http://www.biotimeinc.com/management.htm
 

 

Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at: http://www.michaelwest.org/


 

 

 

 

Recent News: 

http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1152&GoTopage=&Category=1802&t=
 

 

http://finance.yahoo.com/q/h?s=BTX+Headlines

 

Subsidiaries
http://www.biotimeinc.com/subsidiaries/


 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000876343&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038

 

Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

isegall@biotimemail.com

Phone:  510.521.3390 ext 301

 

 

 


 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.

  

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTX
Current Price
Volume:
Bid Ask Day's Range
Wiki
BTX News: Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision 05/04/2015 08:00:00 AM
BTX News: Current Report Filing (8-k) 05/04/2015 07:56:22 AM
BTX News: Current Report Filing (8-k) 04/29/2015 09:02:49 AM
BTX News: BioTime’s Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Stu... 04/27/2015 09:00:00 AM
BTX News: Current Report Filing (8-k) 04/27/2015 08:56:34 AM
PostSubject
#542   Soooo true that! And one with a perfect tradetrak 05/04/15 09:16:01 PM
#541   DNA TECHNOLOGY AND STEM CELL RESEARCH, BIOTIME LEADER envirogym 05/04/15 12:42:54 PM
#540   BTX like owning a biotech portfolio in one stock. poonch1ne 05/04/15 10:28:18 AM
#539   Onward to $10! BTX Stock Guy777 05/04/15 09:54:25 AM
#538   BIOTIME owns and has a whole slew of envirogym 05/01/15 04:36:32 PM
#537   No problem with co-venturing but I thought WE tradetrak 04/30/15 10:05:25 PM
#536   THE PROOF IS IN THE DETAILS, CO-VENTURING IS envirogym 04/30/15 04:43:32 PM
#535   What's with the "Users of BioTime's hES cells tradetrak 04/29/15 08:03:13 PM
#534   Nice expansion on the info I saw on tradetrak 04/22/15 10:38:09 PM
#533   $BTX recent news/filings stocktrademan 04/22/15 12:04:48 PM
#532   THIS IS WHERE THE FUN BEGINS! Pluripotent stem cells. ALAMEDA, Stock Guy777 04/22/15 10:03:24 AM
#531   Yes. I expected more of a move on tradetrak 04/20/15 08:08:02 PM
#530   MORE POSITIVE RESULTS IN BLADDER CANCER CLINICAL TEST! envirogym 04/20/15 03:37:55 PM
#529   With nice volume! :) tradetrak 04/13/15 05:54:07 PM
#528   Nice close! TheHound 04/13/15 04:29:35 PM
#527   Lift off! $10 plus soon! poonch1ne 04/13/15 11:46:15 AM
#526   Someone was asking earlier what the board thought tradetrak 04/08/15 10:56:04 PM
#525   IMO the warrants are extremely attractive. They h2145h 04/08/15 10:41:13 PM
#524   ABOUT TIME THIS PUPPY STARTED MOVING! envirogym 04/08/15 06:13:40 PM
#523   ANY DAY NOW, INSTITUTIONS AND BIG PHARMA COMING! envirogym 04/03/15 02:25:34 PM
#522   LOL... The whole bio index was down but tradetrak 04/01/15 09:15:22 PM
#521   price action and volume pretty amazing, goes to poonch1ne 04/01/15 12:30:21 PM
#520   GO BTX! Years of waiting are going to Stock Guy777 04/01/15 09:40:25 AM
#519   No doubt, Dr. West was quoted saying his poonch1ne 03/31/15 11:41:13 PM
#518   :-) I can feel it! BTX! Stock Guy777 03/31/15 09:58:51 PM
#517   I think this is going to be one tradetrak 03/31/15 09:54:17 PM
#516   BTX app for APPL LifeMap Solutions, an emerging Stock Guy777 03/31/15 01:43:55 PM
#515   BTX app for APPL LifeMap Solutions, an emerging Stock Guy777 03/31/15 01:42:23 PM
#514   We almost saw a major short squeeze recently. Adi2 03/28/15 01:41:34 AM
#513   Love this stock. I in and out of billionareboysclub 03/27/15 10:35:12 AM
#512   Not gonna work for long :) tradetrak 03/27/15 09:45:14 AM
#511   Really trying to keep this under $5 poonch1ne 03/26/15 10:09:28 AM
#510   Nice man, portfolio cornerstone 4 the future. poonch1ne 03/24/15 11:27:21 PM
#509   View this email in your browser BioTime CEO Dr. Stock Guy777 03/24/15 09:41:04 PM
#508   Very nice Argora Financial! I love the video Stock Guy777 03/24/15 09:00:59 PM
#507   In since 2010. Wish I bought more One Flap 03/24/15 08:56:47 PM
#506   You better believe it. I've held the stock Stock Guy777 03/24/15 04:10:27 PM
#505   No suprise if we hit $10 very soon. poonch1ne 03/24/15 10:55:14 AM
#504   Close over $5 yesterday, great sign. Institutes should poonch1ne 03/24/15 10:50:34 AM
#503   Well,while I'm delighted by the Apple connection, I tradetrak 03/20/15 08:29:09 PM
#502   BIOTIME ALSO LEADER IN TODAYS GENE TECHNOLOGY! envirogym 03/20/15 03:28:57 PM
#501   OncoCyte Announces Availability of Abstracts With New Clinical Adi2 03/20/15 01:44:49 PM
#500   Yeah no kidding me too. I did buy Stock Guy777 03/20/15 11:21:21 AM
#499   Wow. I read that in a press release tradetrak 03/19/15 03:40:13 PM
#498   Apple association!!!!!! Especially after reading this! BioTime (NYSE: BTX) 16.3 Stock Guy777 03/19/15 03:05:07 PM
#497   BTX doubles with a close over 5. Check poonch1ne 03/19/15 11:06:19 AM
#496   ONE HELL OF A LOT OF RESEARCH PEOPLE envirogym 03/18/15 10:23:36 PM
#495   Stock Guy777, for the life of me I envirogym 03/12/15 05:04:44 PM
#494   Icahn School of Medicine at Mount Sinai and alien42 03/10/15 12:36:52 PM
#493   Wonder what's up with our hot little subsidiary, tradetrak 03/09/15 08:58:11 PM
PostSubject